Predict your next investment

HEALTHCARE | Drug Development
metys-pharma.ch

See what CB Insights has to offer

Founded Year

2013

Stage

Acquired | Acquired

Total Raised

$60K

About Metys Pharmaceuticals

Metys Pharmaceuticals is developing MP-101 to prevent and treat chemotherapy-induced peripheral neuropathy, an uncomfortable side effect of several important cancer treatments.On September 7th, 2021, Metys Pharmaceuticals was acquired by Novaremed. Terms of the transaction were not disclosed.

Metys Pharmaceuticals Headquarter Location

Gerbergasse 30

Basel, 4001,

Switzerland

+41 79 408 7982

Latest Metys Pharmaceuticals News

Novaremed acquires Basel-based Metys Pharmaceuticals

Sep 14, 2021

Success 14.09.2021 The acquisition of Metys broadens Novaremed’s pipeline focused on novel, non-opioid development candidates for chronic pain indications with the addition of two complementary development projects. Among them is the patented Phase 2 clinical candidate MP-101. Novaremed , a privately-held clinical-stage biopharmaceutical company, announces the acquisition of Metys Pharmaceuticals AG (Metys), including all of its development programs, in an all-share transaction. The acquisition broadens Novaremed’s existing pipeline by adding both clinical and preclinical development projects based on an innovative approach for non-opioid chronic pain treatment, the company’s focus area. From now on, Novaremed’s pipeline to address neuropathic pain will focus on three non-opioid development projects with entirely different modes of action. The company’s candidate NDR NRD.E1, an orally active small molecule with a novel mechanism of action and patent protection until 2040. It acts as a Lyn kinase modulator and is the lead compound being developed to treat painful diabetic peripheral neuropathy (PDPN), affecting 1 in five diabetic patients. With positive results from Phase 2a dose-finding proof-of-concept study, an FDA Fast Track Designation and IND-approval Novaremed is ready to proceed with a 12-week Phase 2b study in patients with moderate to severe PDPN in the US. The newly acquired candidate MP-101, a Phase 2 clinical candidate, is an orally available modulator of glutamate signaling. It works by preventing or reversing the ramped-up signaling that occurs in the spine and brain due to damaged peripheral nerves. MP-101 is a patented non-racemic mixture of dimiracetam enantiomers with patent protection until 2039. Based on positive results from Phase 1 and Phase 2 clinical studies, MP-101 is being developed to manage chemotherapy-induced neuropathy and neuropathic pain. The Phase 2 trial is expected to start in the first quarter of 2023. Another candidate, MP-103, a glutamate signaling modulator orally active in diverse rodent models for preventing and treating peripheral nerve injury symptoms, is set to start Phase 1 clinical development in the first half of 2023.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Metys Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Metys Pharmaceuticals is included in 1 Expert Collection, including Cancer.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Metys Pharmaceuticals Patents

Metys Pharmaceuticals has filed 2 patents.

The 3 most popular patent topics include:

  • Neurological disorders
  • Amines
  • Analgesics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/30/2018

8/11/2020

Psychiatric diagnosis, Neurological disorders, Analgesics, Amines, Piperidines

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

5/30/2018

00/00/0000

Grant Date

8/11/2020

00/00/0000

Title

Subscribe to see more

Related Topics

Psychiatric diagnosis, Neurological disorders, Analgesics, Amines, Piperidines

Subscribe to see more

Status

Grant

Subscribe to see more

Metys Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Metys Pharmaceuticals Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.